Bio-Connect
Chemical Structure
Chemical Structure
Chemical Structure

Ixazomib [MLN2238] [1072833-77-2]

AG-CR1-3670
AdipoGen Life Sciences
CAS Number1072833-77-2
Product group Chemicals
Estimated Purity>98%
Molecular Weight361
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Ixazomib [MLN2238]
  • Delivery Days Customer
    10
  • CAS Number
    1072833-77-2
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Danger
  • Molecular Formula
    C14H19BCl2N2O4
  • Molecular Weight
    361
  • Scientific Description
    Chemical. CAS: 1072833-77-2. Formula: C14H19BCl2N2O4. MW: 361. Synthetic. Potent selective and reversible proteasome inhibitor (all proteolytic subunits). Targets the chymotrypsin-like beta5 subunit of the constitutive 20S proteasome (IC50=3.4nM). Cross-reacts and inhibits the trypsin-like beta2 subunit (IC50=3.5microM) and the caspase-like/peptidyl-glutamyl peptide-hydrolyzing (PGPH) beta1 subunit (IC50=0.03microM). Anticancer compound effective in cell-based assays, in xenografts and against multiple myeloma in vivo. In vitro, induces cell cycle arrest and apoptosis in human cancer cell lines including multiple myeloma. Biologically active form of the prodrug MLN9708 (AG-CR1-3671). Exhibits improved pharmacodynamics and antitumor activity compared to bortezomib in various B-cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic response and antitumor activity in several tumor xenograft models. - Potent selective and reversible proteasome inhibitor (all proteolytic subunits). Targets the chymotrypsin-like beta5 subunit of the constitutive 20S proteasome (IC50=3.4nM). Cross-reacts and inhibits the trypsin-like beta2 subunit (IC50=3.5microM) and the caspase-like/peptidyl-glutamyl peptide-hydrolyzing (PGPH) beta1 subunit (IC50=0.03microM). Anticancer compound effective in cell-based assays, in xenografts and against multiple myeloma in vivo. In vitro, induces cell cycle arrest and apoptosis in human cancer cell lines including multiple myeloma. Biologically active form of the prodrug MLN9708 (Prod. No. AG-CR1-3671). Exhibits improved pharmacodynamics and antitumor activity compared to bortezomib (Prod. No. AG-CR1-3602) in various B cell lymphoma models, due to a greater tumor to blood ratio of proteasome inhibition that ultimately translates into improved tumor pharmacodynamic response and antitumor activity in several tumor xenograft models.
  • SMILES
    OB([C@H](CC(C)C)NC(CNC(C1=C(Cl)C=CC(Cl)=C1)=O)=O)O
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

Related products

Product group Chemicals
AbMole BioScience
MLN2238M2285
CAS Number1072833-77-2
Estimated Purity>99%
Molecular Weight361.03
  • SizePrice
Product group Chemicals
Biorbyt
IxazomibORB1306436
CAS Number1072833-77-2
Estimated Purity98.07%
Molecular Weight361.03
  • SizePrice
Product group Chemicals
MedChem Express
IxazomibHY-10453
CAS Number1072833-77-2
Estimated Purity99.85
Molecular Weight361.03
  • SizePrice
Product group Chemicals
RayBiotech
MLN2238331-10818
  • SizePrice
Product group Chemicals
Biosynth
CAS Number1072833-77-2
Molecular Weight361.03 g/mol
  • SizePrice
Product group Chemicals
Santa Cruz Biotechnology
CAS Number1072833-77-2
  • SizePrice
Ixazomib [1072833-77-2]
Product group Chemicals
References
TargetMol Chemicals
CAS Number1072833-77-2
Estimated Purity98.07%
Molecular Weight361.03
  • SizePrice